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Abstract: Procarbazine HCl is a ‘nonclassical’ oral alkylating anticancer agent that was first
synthesized in the late 1950s. It has been used in the treatment of many cancers, but its main use
is in the treatment of Hodgkin’s lymphoma and brain tumors and, to a lesser extent, Non-Hodgkin’s
lymphoma and primary central nervous system lymphoma. Procarbazine is a prodrug that undergoes
metabolic transformation into active intermediates that are thought to inhibit DNA, RNA, and
protein synthesis. Early use of procarbazine in combination with mechlorethamine, vincristine,
and prednisone (MOPP) was effective in the treatment of advanced Hodgkin’s lymphoma, but late
toxic effects such as secondary cancer and infertility led to its replacement by other regimens.
However, its recent reintroduction in the dose-intensified BEACOPP (bleomycin, etoposide,
doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) regimen has yielded
very promising findings. Procarbazine alone, or more commonly combined in the PCV (procarbazine,
lomustine [CCNU], and vincristine) regimen, is also effective in treating gliomas comprising
astrocytomas, glioblastomas, and oligodendrogliomas. The most common side effects of
procarbazine are gastrointestinal disturbances, myelosuppression, and central nervous system
effects. In conclusion, the use of procarbazine in combination with other drugs means that it
remains a major anticancer drug in the management of Hodgkin’s lymphoma
and gliomas.
Keywords: procarbazine, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, lymphoma, brain
tumor, glioma
Introduction
Procarbazine HCl is a ‘nonclassical’ oral alkylating agent that belongs to the same
family as dacarbazine and hexamethylamine (Zeller et al 1963). It contains an N-methyl
group that is essential for its activity, but not the chloroethyl group that is present in
nitrogen mustard-type alkylating agents (Newell et al 1987). It was first synthesized in
the late 1950s during a search for a new monoamine oxidase inhibitor, but was soon
developed as an anticancer agent (Kenis et al 1966; Martin and Schubert 1966; Livingston
and Carter 1970; Friedman 2001) and has since been used in the treatment of many
cancers including Hodgkin’s lymphomas, non-Hodgkin’s lymphoma, brain tumors,
multiple myeloma, primary central nervous system lymphoma, malignant melanoma,
and lung cancer.
Procarbazine was first granted approval in 1965 and was subsequently marketed in
around 84 countries. It has been widely deployed in the treatment of a number of
cancers and a considerable body of clinical experience with this drug has accumulated.
The introduction of safer combination therapies led to the gradual supplantation of
procarbazine. During recent years, there has been a re-emergence of interest in
procarbazine combinations with other chemotherapeutic agents, specifically for the
treatment of Hodgkin’s lymphoma and gliomas and, to a lesser extent, non-Hodgkin’s
lymphoma and primary central nervous system lymphoma. This is partly prompted byTherapeutics and Clinical Risk Management 2007:3(2) 214
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the unique mechanism of action of procarbazine; this agent
has multiple sites of action and is not cross-resistant with
other alkylating agents, cytostatics or radiotherapy (Matche
et al 1963; Brunner and Young 1965).
Reintroduction of procarbazine in the dose-intensified
BEACOPP (bleomycin, etoposide, doxorubicin, cyclophospha-
mide, vincristine, procarbazine, and prednisone) regimen has
yielded impressive therapeutic results in the treatment of
Hodgkin’s lymphoma and, in combination with lomustine
(CCNU) and vincristine in the PCV (procarbazine, CCNU,
and vincristine) regimen, it shows considerable promise in
the treatment of gliomas.
Preclinical studies
Pharmacology
Procarbazine is a prodrug that undergoes a complex metabolic
transformation into active intermediates. Although these
intermediates have been characterized, their precise
mechanism of action remains unclear. They are thought to
inhibit DNA, RNA, and protein synthesis (Berneis et al 1963;
Rutinshauser and Bollag 1963). Studies suggest that
procarbazine may inhibit transmethylation of the methyl
groups of methionine into t-RNA; the subsequent lack of
functional t-RNA could cause cessation of protein synthesis,
and consequently DNA and RNA synthesis. DNA may also
be damaged directly by hydrogen peroxide, formed during
auto-oxidation of procarbazine, which may attack the protein
sulphydryl groups in residual protein that is tightly bound to
DNA. These effects are specific for the S and G2 phases of
the cell cycle. Drug resistance mechanisms to procarbazine
also indicate that the methylating pathway is important in its
mechanism of action and may help to develop new therapeutic
strategies. Potential resistance mechanisms involve O
6-
alkylguanine DNA alkyltransferase (AGT)-mediated repair
of O
6-methylguanine activity and hMSH2 mismatch-repair
deficiency (Pegg 1990; Friedman et al 1997).
In vivo, significant antitumor activity has been
demonstrated against Ehrlich carcinoma and Crocker sarcoma
S180 in mice, and Walker carcinoma 256, Guerin uterine
carcinoma T8, and intracerebral leukemia L1210 in rats
(Bollag and Grunberg 1963).
Toxicology
Mutagenic effects of procarbazine have been demonstrated
in a variety of bacterial and mammalian test systems, and it
has been shown to inhibit fetal development in rats (Malek
et al 2003). Unscheduled DNA synthesis in the testes of
rabbits has also been reported (Zbinden 1980). As might be
expected with an agent that inhibits DNA, RNA, and /or
protein synthesis, reduced fertility has been seen in male
mice given procarbazine (Chryssanthou et al 1983).
Carcinogenic effects of procarbazine have been reported
in mice, rats, and monkeys.
Pharmacokinetics and drug
disposition
Procarbazine is quickly and completely absorbed from the
gastrointestinal tract following oral administration, with peak
plasma levels achieved after 0.5–1 hour (Supko et al 2002; Preiss
et al 2006). It readily crosses the blood-brain barrier and peak
cerebrospinal fluid levels are reached after 0.5–1.5 hours.
The half-life of procarbazine is about 10 minutes and it is
rapidly and extensively metabolized by the liver. Oxidation
of procarbazine to azo-procarbazine occurs by microsomal
cytotchrome P450 oxidoreductase, as well as by
mitochondrial monoamine oxidase enzymatic conversion.
Plasma levels of azo-procarbazine are notably higher than
those of procarbazine itself. Azo-procarbazine is
microsomally oxidized to azoxyderivatives. Of these,
methylazoxy-procarbazine appears to be the major cytotoxic
compound, showing several-fold greater cytotoxicity than
procarbazine, azo-procarbazine, and benzyazoxy-
procarbazine (Erikson et al 1989). Plasma levels of
methylazoxy-procarbazine peak after about 1.5 hours and it
has a half-life of around 1 hour.
About 70% of the dose is renally excreted in the first 24
hours; the major urinary metabolite is the biologically inactive
N-isopropylterphthalamic acid. The majority of the remainder
is excreted via the respiratory system, with only minimal fecal
excretion. Impaired renal or hepatic function can delay
elimination of procarbazine and its active metabolites.
Clinical efficacy
Lymphomas
Hodgkin’s lymphoma
Hodgkin’s lymphoma affects approximately 8000 new
patients each year in the USA and around 1500 in the UK,
occurring most commonly in young adults and in people
who are more than 55 years old (Glaser and Jarrett 1996; ACS
2006). Although the management of the disease has improved
considerably in recent years, around 20% to 30% of patients
still experience disease progression or relapse.
Early studies reported overall response rates of 53% to
69% with single agent procarbazine in patients with advancedTherapeutics and Clinical Risk Management 2007:3(2) 215
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Hodgkin’s lymphoma (Brunner and Young 1965; Livingston
and Carter 1970). However, these responses were generally
very short-lived and there were few complete responses. In
the early 1970s, procarbazine was used successfully in
combination with three other drugs in the regimen known as
MOPP (mechlorethamine [nitrogen mustard], Oncovin
®
[vincristine], procarbazine, and prednisone) in the treatment
of advanced Hodgkin’s lymphoma (DeVita et al 1970). A
complete remission rate of 84% was attained, with relapse-
free and overall survival rates of 66% and 48%, respectively,
after more than 20 years. Unfortunately, although the acute
toxic effects of MOPP are manageable, it is associated with
significant long-term toxicity. For example, more than 90%
of men, and 80%–100% of women over 25 years old, become
irreversibly infertile (Pazdur et al 2003). There is also a risk
of secondary acute leukemia, which is frequently resistant to
treatment and has an extremely poor prognosis (Ng et al 2002).
A number of MOPP-like regimens were developed in an
attempt to reduce this toxicity. It would appear that
procarbazine plays an important role in MOPP, as lower
complete remission rates of shorter duration were reported
with MOPP-like regimens that did not contain procarbazine
(Nicholson et al 1970; Luce et al 1971).
ABVD (doxorubicin, bleomycin, vinblastine, and
dacarbazine) subsequently became the regimen of choice for
advanced disease after showing superior efficacy and less
long-term toxicity than MOPP and MOPP hybrid regimens
(Canellos et al 1992; Duggan et al 2003). The combination
of MOPP plus epidoxirubicin, bleomycin, vinblastine,
lomustine, doxorubicin, and vindesine (MOPPEBVCAD) has
recently been suggested to be as effective as ABVD and more
effective than the Stanford V schedule (doxorubicin,
vinblastine, mechlorethamine, vincristine, bleomycin,
etoposide, and prednisone) (Gobbi et al 2005, 2006).
However, despite lower toxicity than normally expected with
MOPP analogues, the incidence of second cancers remains
somewhat higher than with ABVD. It is, nevertheless, a good
option for patients who are not suitable for high-dose
chemotherapy.
C-MOPP/ABV, a hybrid chemotherapy in which
cyclophosphamide is substituted for mechlorethamine
(which has been implicated as the cause of secondary
malignancies) has shown beneficial effects (Montoto et al
2000). In 73 patients with advanced disease, 57 (78%)
achieved a complete response and 7 further patients who
achieved partial response reached complete response after
radiotherapy (Monoto et al 2000). The overall survival rate
after 4 years was 92%. In another study in which dacarbazine
was added to the regimen (C-MOPP-ABVD), a response rate
of 93% and a complete response rate of 84% was achieved
amongst the 67 patients (Takenaka et al 2000).
A recent report of the long-term follow-up of 533 patients
with advanced Hodgkin’s lymphoma indicated that ABVPP
(doxorubicin, bleomycin, vinblastine, procarbazine, and
prednisone) was associated with a better survival probability
than MOPP-ABV (Ferme et al 2006). The 10-year overall
survival estimates were 90% for ABVPP, 78% for MOPP-ABV ,
82% for MOPP-ABV and radiotherapy, and 77% for ABVPP
and radiotherapy (p = 0.03).
The German Hodgkin’s Study Group developed a new
combination regimen known as BEACOPP, based on a
statistical model that considers tumor growth and chemothera-
peutic effects (Loeffler et al 1998). The dose of procarbazine
is 100 mg/m
2 over 7 days, which is half that delivered over 14
days in the MOPP regimen. Both regimens are given on a
21-day cycle. In a randomized study, 1195 patients with newly
diagnosed Hodgkin’s lymphoma in an unfavorable stage (IIB,
IIIA, IIIB, or IV) were randomized to receive eight cycles of
COPP-ABVD (alternating cyclophosphamide, vincristine,
procarbazine, and prednisone with doxorubicin, bleomycin,
vinblastine, and dacarbazine), standard-dose BEACOPP, or
increased-dose BEACOPP (Table 1), each followed by local
radiotherapy when indicated (Diehl et al 2003). The outcome
of treatment and five-year survival rates are shown in Table
2. The increased-dose BEACOPP regimen was significantly
(pd ≤ 0.002) more effective than COPP-ABVD in terms of
freedom from treatment failure (87% vs 69%) and overall
survival (91% vs 83%) at 5 years, as well as early progression
(2% vs 10%). Standard-dose BEACOPP was also signifi-
cantly (p = 0.04) more effective than COPP-ABVD for
freedom from treatment failure at 5 years (76% vs 69%).
When the two BEACOPP regimens were compared with
each other, the increased-dose regimen resulted in a
significantly lower rate of early progression (2% vs 8%)
and a significantly (p < 0.001) greater freedom from
treatment failure at 5 years (87% vs 76%). Acute
hematological effects were more common with the
increased-dose BEACOPP regimen. The actuarial rate of
secondary acute leukemia five years after diagnosis of
Hodgkin’s disease was also significantly (p  =  0.03) higher
with increased-dose BEACOPP (2.5%) compared with
standard-dose (0.6%), and COPP-ABVD (0.4%).
The acute hematological toxicity of standard-dose and
dose-intensified BEACOPP was investigated in 858 patientsTherapeutics and Clinical Risk Management 2007:3(2) 216
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with advanced Hodgkin’s lymphoma (Engel et al 2000).
Dose-limiting toxicity occurred in 25% of cycles of dose-
intensified treatment, but severe thrombocytopenia and
leukocytopenia were rare. Myelosuppression was the most
important dose-limiting factor. The findings indicated that,
despite some increase in hemotoxicity, moderate dose
escalation was safe for most patients receiving granulocyte
colony-stimulating factor (G-CSF) and standard supportive
treatment.
BEACOPP has also been used successfully as salvage
treatment in patients with early stage Hodgkin’s lymphoma
who relapsed after extended field radiotherapy. A
retrospective analysis of 107 patients treated mainly with
COPP-ABVD-like regimens (n = 74) or BEACOPP (n = 24)
showed that BEACOPP was significantly (p = 0.02) superior
to the other regimens, with 100% of patients achieving
complete remission compared with 85% of those given
COPD-ABVD-like regimens, and 67% given other regimens
including radiotherapy (Rüffer et al 2005). BEACOPP was
also a significant (p = 0.03) prognostic factor for freedom
from second failure.
In a study in children and adolescents with advanced
disease, induction treatment with dose-intensified BEACOPP
improved early tumor control, with a 45% response rate
(>70% reduction in disease burden) after 2 cycles and a 72%
response rate after 4 cycles (Kelly et al 2002).
Non-Hodgkin’s lymphoma
Single-agent procarbazine is less active in non-Hodgkin’s
lymphoma than in Hodgkin’s lymphoma, resulting in overall
response rates of only around 36%–40% (Livingston and Carter
1970), although it has a role to play for patients who fail
standard regimens or who cannot tolerate or refuse such
treatment (Chaar et al 2006). Combination regimens
containing procarbazine, such as MOPP and COPP
(cyclophosphamide, Oncovin
® [vincristine], procarbazine, and
prednisone), have resulted in more beneficial effects,
particularly in patients with advanced stage nodular mixed or
lymphocytic poorly differentiated disease (Lowenbraun et al
1970; DeVita et al 1975; Longo et al 1984; Ezdinli et al 1985).
The best response rates to regimens containing procarbazine
are seen with intensive cyclic multi-drug combinations such
as ProMACE-MOPP (procarbazine, methotrexate with
leucovorin, doxorubicin, cyclophosphamide, and etoposide).
In a randomized, controlled trial, 221 patients with diffuse
intermediate- to high-grade non-Hodgkin’s lymphoma
received ProMACE-MOPP for 6 cycles or the newer generation
more aggressive MACOP-B (methotrexate with leucovorin,
doxorubicin, cyclophosphamide, vincristine, prednisone, and
bleomycin) for 12 weeks (Sertoli et al 1994). There was no
significant difference between the ProMACE-MOPP and
MACOP-B groups in terms of complete remission rate (49.1%
and 52.3%), three-year overall survival rate (45.2% and 52.3%),
and three-year progression-free survival rate (36.4% and
36.1%). Toxicity was also similar with both treatments. THP-
COPBLM (pirarubicin, cyclophosphamide, vincristine,
prednisone, bleomycin, and procarbazine) combined with G-
CSF in 42 patients with intermediate- or high-grade non-
Hodgkin’s lymphoma resulted in a complete remission rate of
88% and a partial remission rate of 12% (Niitsu and Umeda
1998). The 3-year survival rate was 72% and the 3-year event-
free survival rate was 58%. In 51 older patients (e ≥ 55 years
old) with intermediate-grade non-Hodgkin’s lymphoma,
COPBLAM-I (cyclophosphamide, vincristine, prednisone,
Table 1 COPP-ABVD, standard-dose BEACOPP, and increased-dose BEACOPP dosage regimens (Diehl et al 2003)
COPP-ABVD
a Standard-dose BEACOPP
b Increased-dose
BEACOPPb
Single dose Days Single dose Days Single dose Days
(mg/m
2) given (mg/m
2) given (mg/m
2) given
Bleomycin 10 iv 29 and 43 10 iv 8 10 iv 8
Etoposide - - 100 iv 1–3 200 iv 1–3
Doxorubicin 25 iv 29 and 43 25 iv 1 35 iv 1
Cyclophosphamide 650 iv 1 and 8 650 iv 1 1200 iv 1
Vincristine 1.4 iv 1 and 8 1.4 iv 8 1.4 iv 8
Procarbazine 100 po 1–14 100 po 1–7 100 po 1–7
Prednisone 40 po 1–14 40 po 1–14 40 po 1–14
Vinblastine 6 iv 29 and 43 - - - -
Dacarbazine 375 iv 29 and 43 - - - -
Note: aregimen repeated on day 57; bregimen repeated on day 22.
Abbreviations: BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone; COPP-ABVD, alternating
cyclophosphamide, vincristine, procarbazine, and prednisone with doxorubicin, bleomycin, vinblastine, and dacarbazine; iv, intravenous; po, oral.Therapeutics and Clinical Risk Management 2007:3(2) 217
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bleomycin, doxorubicin, and procarbazine) resulted in a
complete remission rate of 65% after a median follow-up of
2.4 years (Shpilberg et al 1994). The projected 3-year overall
survival and progression-free survival rates were 58% and 77%,
respectively.
Primary central nervous system lymphoma
Primary central nervous system lymphoma is an aggressive
non-Hodgkin’s lymphoma arising in the brain, eyes, spinal
cord, or leptomeninges. The incidence has increased markedly
over the last two decades, both in patients with and without
immunodeficiency (Corn et al 1997).
Although the use of radiotherapy prior to methotrexate
improves survival in these patients, it is also associated with
neurotoxic effects, such as severe cognitive dysfunction and
ataxia (DeAngelis et al 1989). This is a particular problem
because at least half of all patients are at least 60 years old at
the time of diagnosis. To avoid this problem, a number of
chemotherapeutic regimens have been investigated as sole
therapy. Procarbazine crosses the blood-brain barrier and has
therefore been included in some of these regimens.
In a study of 52 patients treated with 5 cycles of high-
dose methotrexate, procarbazine, and vincristine, with or
without whole-brain radiotherapy, the objective response rate
was 90% and the median survival 60 months (Abrey et al
2000). The median survival was similar amongst the older
patients (>60 years old), irrespective of whether or not they
received radiotherapy, but late neurotoxicity was significantly
(p = 0.0004) more common in those who received radiotherapy.
Another study, conducted by the European Organisation for
Research and Treatment of Cancer (EORTC) Brain Tumour
Group in 50 elderly patients (median age 72 years), investigated
the use of high-dose methotrexate, lomustine, procarbazine,
methylprednisolone, and intrathecal chemotherapy with
methotrexate and cytarabine (Hoang-Xuan et al 2003). The
objective response rate was 48% (42% complete and 6% partial
responses); the median duration of the response in the patients
with complete response was 27 months; the median survival
was 14.3 months; and the one-year progression-free survival
was 40%. The majority of patients had improved or preserved
cognitive function and Karnofsky performance scores (KPS)
until relapse. A decline in cognitive function and KPS attributed
to late neurotoxicity occurred in only 8% and 12% of patients,
respectively. In the long-term responders who were in remission
2 years after the start of therapy, only one patient showed a
decline in cognitive function or performance status due to
delayed neurotoxicity. This outcome was superior to that
expected with radiotherapy alone in elderly patients and
considerably reduced the risk of delayed neurotoxicity.
Blood-brain barrier disruption (BBBD) results in
enhanced chemotherapy delivery. In 74 patients who
underwent BBBD preceded by systemic cyclophosphamide
and followed by intra-arterial methotrexate in combination
with procarbazine and dexamethasone, a complete response
Table 2 Outcome of treatment and five-year survival rates with COPP-ABVD, standard-dose BEACOPP, and increased-dose
BEACOPP (Diehl et al 2003)
COPP-ABVD Standard-dose BEACOPP Increased-dose BEACOPP
(n = 260) (n = 469) (n = 466)
Complete remission 85 (80–89) 88 (85–91) 96 (93–97)
Early progression 10 (7–15) 8 (5–10) 2 (1–4)**†
Freedom from treatment 69 (63–75) 76 (72–80)* 87 (83–91)**
†
failure at 5 years
Overall survival at 5 years 83 (78–87) 88 (85–91) 91 (88–94)*
Note: Values given as percentage (95% confidence interval); Early progression defined as progression during treatment or within 3 months after the end of treatment;
*p < 0.05 vs COPP-ABVD; **p < 0.001 vs COPP-ABVD; †p < 0.001 vs standard-dose BEACOPP.
Abbreviations: BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone; COP-ABVD, alternating
cyclophosphamide, vincristine, procarbazine, and prednisone with doxorubicin, bleomycin, vinblastine, and dacarbazine.
Table 3 PCV and intensified PCV regimens
PCV Intensified PCV Days of administration Frequency
Procarbazine 60 mg/m
2 po 75 mg/m
2 po 8–21 Every 6–8 weeks
Lomustine 110 mg/m2 po 130 mg/m2 po 8 and 29
Vincristine 1.4 mg/m
2 iv 1.4 mg/m
2 iv 1
Abbreviations: PCV, procarbazine, lomustine (CCNU), vincristine.Therapeutics and Clinical Risk Management 2007:3(2) 218
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was achieved in 65% (n = 48) and a partial response in 19%
(n = 14) (McAllister et al 2000). Amongst the 36 patients
who continued to show a complete response after one year,
none had any evidence of cognitive loss.
Procarbazine has also been used as part of the PCV
(procarbazine, CCNU, and vincristine) regimen. Although the
prognosis at relapse is often poor for patients suffering from
primary central nervous system lymphoma, treatment of 7
relapsed patients with PCV resulted in a complete response
in 4 and a partial response in 2 (Herrlinger et al 2000).
Brain tumors—glioma/astrocytoma
Gliomas comprise about half of all primary brain tumors and include
astrocytomas, glioblastomas, and oligodendrogliomas. The dosage
details for the PCV and intensified PCV regimens are shown in
Table 3. A summary of the main clinical trials into the use of single-
agent procarbazine and procarbazine-containing regimens in
patients with glioma is provided in Table 4.
Interest in the use of procarbazine emerged around 1990
when data from the Northern California Oncology Group was
reanalyzed to compare the effects of carmustine (BCNU) with
that of PCV following radiation/oral hydroxyurea in patients
with glioblastoma multiforme or other anaplastic gliomas
(Levin et al 1990). PCV treatment resulted in longer survival
and time to tumor progression than BCNU, with the difference
achieving statistical significance in the group of patients with
anaplastic gliomas.
In a randomized study of 171 patients with grade III/IV
astrocytoma given PCV , with or without radiotherapy, the
median time to progression was 21 weeks and the median
survival time was 53 weeks (Sandberg-Wollheim et al 1991).
Overall, 18% of patients survived for at least two years.
Survival analysis showed that the best responses were
achieved in patients less than 50 years old who received both
PCV and radiotherapy (median time to progression and
survival time of 81 and 124 weeks, respectively).
A durable response to PCV was reported by Kim and
colleagues (1996) in 32 patients with grade III/IV oligoastro-
cytoma or anaplastic oligodendroglioma. The PCV therapy was
administered every 6 weeks for a total of at least 124 cycles.
The median duration of follow-up review from the start of
chemotherapy was 19.3 months. Grade 3 or 4 hematological
toxicity was experienced by nine (31%) of 29 patients. Ten
patients had delayed treatment due to treatment-related toxicities
(34.5%). Ninety-one percent of the 32 patients responded to
the therapy. These included 10 patients with a complete response
and 19 with a partial response. The median time to progression
was 15.4 months for all patients and 23.2 months for those
with Grade III tumors. The median time to progression for
patients with Grade III oligoastrocytomas was 13.8 months;
for those with Grade IV oligoastrocytoma it was 12.4 months,
and for those with anaplastic oligodendrogliomas it was 63.4
months (p = 0.0348). These patients survived a median of 49.8
months, 16 months, and 76 or more months, respectively, from
the start of chemotherapy (p = 0.0154), thus showing that PCV
therapy provides durable responses in patients with Grade III
or IV oligoastrocytomas.
A number of other studies found no marked beneficial
effects of PCV therapy on survival (Prados et al 1999;
Kappelle et al 2001; MRC 2001) and so there has been an
increasing tendency to use procarbazine as a salvage option.
However, little data are available in the literature regarding
this strategy (Rodriguez et al 1989; Newton et al 1990;
Brandes et al 1999; Newlands et al 2003). Response rates of
15% to 25% were reported with single-agent procarbazine in
patients with recurrent glioblastoma or anaplastic astrocytoma
(Rodriguez et al 1989; Newton et al 1990). An overall response
rate of 30% was achieved with combined procarbazine and
tamoxifen in patients with high-grade gliomas that recurred
after surgery and radiotherapy (Brandes et al 1999). Compared
with patients suffering from glioblastoma, those with
anaplastic astrocytoma had a significantly longer median time
to progression (33 vs 13 weeks) and median survival time
(57 vs 27 weeks).
Recent results of adjuvant PCV in newly diagnosed patients
with anaplastic oligodendroglioma are extremely encouraging
(Buckner et al 2003; Stege et al 2005; van den Bent et al 2005,
2006; Yamamoto et al 2005). PCV resulted in tumor regression
in a meaningful proportion of newly diagnosed low-grade
oligodendroglioma, with or without loss of 1p/19q. In a phase
III EORTC study (van den Bent et al 2005, 2006), 6 cycles of
adjuvant PCV following radiotherapy in 368 patients with
highly anaplastic oligodendroglioma prolonged the progress-
ion-free survival from 13 to 23 months compared with
radiotherapy alone (p = 0.0018) (Figure 1). Overall survival
was also longer with adjuvant PCV , but the difference did not
reach statistical significance (Figure 1). The percentage of
patients with progression-free survival after 2 years and overall
survival after 5 years also showed advantages for adjuvant PCV
treatment (Figure 2). Recent evidence suggests that PCV may
also be beneficial in patients with symptomatic low-grade
oligodendroglioma (Catenoix et al 2006).
Beneficial effects were reported with 6-thioguanine,
procarbazine, dibromodulcitol, lomustine, and vincristineTherapeutics and Clinical Risk Management 2007:3(2) 219
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Figure 1 Median progression-free survival and overall survival in patients with newly diagnosed anaplastic oligodendroglioma treated with radiotherapy alone or
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Figure 2 Percentage of patients with progression-free survival after 2 years and overall survival after 5 years in patients with newly diagnosed anaplastic
oligodendroglioma treated with radiotherapy alone or radiotherapy plus PCV (procarbazine, CCNU, and vincristine) (van den Bent et al 2006).
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(TPDCV) in 42 children and young people with malignant
astrocytomas (Levin et al 2000). Of the 17 patients with
glioblastoma multiforme, 13 died, the median time to
progression was 49 weeks and median survival was 85 weeks.
Amongst the remaining 25 patients with nonglioblastoma
malignant astrocytoma, 14 died and the median time to
progression was 224 weeks. The median survival was not
reached in this group after a median follow-up of 494 weeks.
The BBSFOP protocol, which comprises seven cycles of three
drug pairs (carboplatin-procarbazine, cisplatin-etoposide and
vincristine-cyclopho-sphamide), was used as first line treatment
to avoid radiotherapy in 21 children (<5 years old) with high-
grade glioma (Dufour et al 2006). The 5-year progression-
free survival was 35% and the 5-year overall survival was
59%, with a median follow-up of 5.2 years. Of the 12 children
still alive, 10 have not required radiotherapy.
Procarbazine, nimustine, and vincristine given in combination
with hyperfractionated radiotherapy resulted in an objective
response in 3 out of 8 patients with high-grade glioma (Ogawa
et al 2006). The median time to progression was 10.7 months
and the median survival time of all patients was 15.0 months.
The treatment was safe and well tolerated.
Recent evidence indicates that enzyme-inducing anti-
seizure medications have no effect on the pharmacokinetics
of procarbazine in patients with glioma, but that there may
be an increased risk of hepatic dysfunction with this drug
combination (Grossman et al 2006).
Safety and tolerability
Gastrointestinal disturbances (eg, nausea and vomiting),
myelosuppression (eg, leukopenia, anemia, and thrombo-
penia) and central nervous system effects (eg, headache,
depression, nervousness, and insomnia) are the most common
side-effects seen with procarbazine, followed by neuromus-
cular problems such as tremor, weakness, and parasthesia.
Procarbazine has also been associated with secondary
nonlymphoid malignancies, including acute leukemia and
solid tumors such as lung cancer, when used in combination
therapy. Azoospermia and adverse effects on female gonadal
function may also be a problem. Rare side-effects include
hemolysis in patients with glucose 6-phosphate dehydro-
genase deficiency, hypersensitivity reactions, eosinophilia,
and pulmonary infiltrates.
Since procarbazine is a weak monoamine oxidase
inhibitor, there is a possibility of interactions with food
containing high levels of tyramine (eg, beer, cheese, wine,
bananas) and with certain drugs such as sympathomimetics
and decongestants. Possible effects include hypertensive
crisis, intracranial bleeding, and headache. Procarbazine can
also interact with other medications. For example, central
nervous system depressants (eg, anesthetics, barbiturates,
narcotic analgesics), drugs with anticholinergic effects (eg,
tricyclic antidepressants), and antihypertensive agents
should all be used with caution and in reduced dosage in
patients taking procarbazine due to possible potentiation
effects. Alcohol should also be avoided as disulfiram-like
effects such as sweating and facial flushing may occur.
Discussion and place in therapy
Procarbazine is a long established anticancer medicine.
Although there is renewed interest in this agent, it is
worthwhile to remember the many patient-years of experience
in many different oncological indications which exist; few
‘new’ cancer therapies have the benefit of such experience.
Although there was a long period in which interest in
procarbazine waned due to safety concerns and the
development of other cancer treatments, interest is currently
re-emerging, mainly in combination with other agents for the
treatment of Hodgkin’s lymphoma and gliomas, for which
procarbazine activity is high. Some of the early combination
therapies which used procarbazine (such as MOPP) were
effective, but their use was limited by late toxicity. The new
generation of procarbazine-containing combination therapies
have been optimized to maximize efficacy and minimize the
late-toxic effects seen with the first combinations.
Procarbazine looks likely to continue in the anticancer
armamentarium for some time to come and, as a component
of the BEACOPP combination, become part of the proposed
‘gold standard’ treatment for Hodgkin’s lymphoma (Massoud
et al 2004). Recent results of adjuvant PCV in newly
diagnosed patients with anaplastic oligodendroglioma are also
extremely encouraging. Despite its long history, procarbazine
is still an important drug in the treatment of Hodgkin’s
lymphoma and gliomas.
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